secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-06-15T20:06:58+00:00
Accession:  0002007919-26-000033
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Inhibrx BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027
--------------------------------------------------------------------------------

- FDA accepted BLA for ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma.
- No filing review issues identified; PDUFA goal date set for April 14, 2027.
- If approved, ozekibart would be first FDA-approved systemic therapy for this indication.
- Pivotal ChonDRAgon trial showed 52% risk reduction in disease progression/death (HR 0.479; p<0.0001).
- Median PFS 5.52 months for ozekibart vs 2.66 months for placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/0002007919-26-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer